Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002365
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of LXR015-1 in HIV-Infected Patients
Sponsor:
LXR Biotechnology
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Randomized Parallel Open-Label Phase I Study of LXR015-1 in HIV-Infected Patients
Status:
COMPLETED
Status Verified Date:
1998-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine and compare the safety and tolerability of 3 doses of LXR015-1 in HIV-infected patients
Detailed Description:
Patients will be randomized to 1 of 3 doses of oral LXR015-1 for 28 days and patients will be monitored for adverse events for the duration of the study Patients will continue to be monitored for least 4 weeks after completion of the dosing
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: